Gliptins: A new class of oral antidiabetic agents

Indian Journal of Pharmaceutical Sciences

Volumn 71, Issue 6, 2009, Pages 608-614

  Seshadri, K G ^a   Kirubha, M H B ^a  

^a SRI RAMACHANDRA UNIVERSITY   (India)

Author keywords

Dipeptidyl peptidase 4 (DPP 4) inhibitors; Glucagon like peptide 1 (GLP 1); Sitagliptin; Type 2 diabetes mellitus

Indexed keywords

6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; ALBIGLUTIDE; ALOGLIPTIN; AMG 222; AVE 0010; BI 1356BS; CJC 1134; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; INCRETIN; INSULIN; LIRAGLUTIDE; MELOGLIPTIN; METFORMIN; METFORMIN PLUS SAXAGLIPTIN; METFORMIN PLUS SITAGLIPTIN; METFORMIN PLUS VILDAGLIPTIN; MP 513; PHX 1149; PLACEBO; PSN 9301; R 1579; R 51077; SAXAGLIPTIN; SITAGLIPTIN; SYR 472; TA 6666; TASPOGLUTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILDAGLIPTIN;

ACUTE HEMORRHAGIC PANCREATITIS; CELL GROWTH; CELL SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATININE CLEARANCE; DIABETIC PATIENT; DIARRHEA; DIZZINESS; DOSE KIDNEY FUNCTION RELATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME REGULATION; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HEADACHE; HORMONE ACTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RELEASE; KIDNEY FAILURE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PANCREATITIS; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; REVIEW; RHINOPHARYNGITIS; STOMACH DISCOMFORT; UPPER RESPIRATORY TRACT INFECTION; WEIGHT CHANGE;

EID: 77249092557     PISSN: 0250474X     EISSN: 19983743     Source Type: Journal    
DOI: 10.4103/0250-474X.59541     Document Type: Review

References (29)

1. Drucker D, Easley C, Kirkpatrick P. Sitagliptin. Nat Rev Drug Discov 2007;6:109-110
2. Baggio LL, Drucker DJ. Incretin hormones in the treatment of type 2 diabetes: Therapeutic applications of DPP-IV inhibitors. Available from: http://www.medscape.com/viewarticle/530215. [cited on 2008 Sep 20].
3. Walsh J. The Incretins: GLP-1 Agonists and DPP-4 Inhibitors. Available from: http://www.diabetesnet.com/diabetes-treatments/ incretins.php. [cited on 2008 Sep 2].
4. Field BC, Wren AM, Cooke D, Bloom SR. Gut hormones as potential new targets for appetite regulation and the treatment of obesity. Drugs 2008:68:147-163
5. Chyan Y, Chuang L. Dipeptidyl Peptidase-IV Inhibitors: An evolving treatment for type 2 diabetes from the incretin concept. Recent Pat Endocr Metab Immune Drug Discov 2007:1:15-24.
6. Cheeseman M, Wright T. A taste of things to come. Inpharma 2008;1640:3-4.
7. White JR. Dipeptidyl peptidase IV inhibitors: Pharmacological profile and clinical use. Clin Diab 2008;26:53-57
8. Bloomgarden Z, Drexler A. What role will 'gliptins' play in glycemic control? Cleve Clin J Med 2008;75:305-310
9. Drucker DJ. The biology of incretin hormones. Cell Metabolism 2006;3:153-165
10. Drucker DJ, Nauck MA. The incretin system: Glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705
11. Sitagliptin: First DPP-4 Inhibitor for Type 2 Diabetes. Resident and Staff Physician 2007;53:4. Available from: http://www.residentandstaff. com/issues/articles/2007-04-05.asp [cited on 2008 Sep 2].
12. New drugs approved for marketing in India. Drugs Control. Available from: http://www.drugscontrol.org/New-drugs-app6.htm [cited on 2008 Oct 1].
13. Buse JB, Polonsky KS, Burant CF. William's Textbook of Endocrinology. 11th ed. Philadelphia: Saunders Elsevier; 2008. p. 1369.
14. Cheeseman M. Incretin mimetics examined at ADA 2008. Inpharma Wkly 2008;1644:3-4.
15. Paddock C. FDA to strengthen warnings on diabetes drug after 2 more deaths. Medical news today Available from: http://www. medicalnewstoday.com/ articles/118614.php. [cited on 2008 Sep 25].
16. Sitagliptin phosphate. FDA Patient Information sheet, Available from: http://www.fda.gov/cder/drug/InfoSheets/patient/sitagliptin- phosphatePIS.pdf 2006. [Cited on 2008 Sept 12]
17. Sitagliptin: New Drug Evaluation. Regional drug and therapeutics centre. Aug 2007;85 Available from: http://www.nyrdtc.nhs.uk/docs/ nde/NDE-85- Sitagliptin-final-a.pdf [cited on 2008 Sep 19].
18. Sitagliptin and Vildagliptin in type 2 diabetes. On the horizon future medicines [online] Available from: http://www.npci.org.uk/therapeutics/ cardio/diabetes2/resources/library- oth-future-medicines-sitagliptin- vildagliptin.pdf [cited on 2008 Oct 1].
19. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the Dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-2637
20. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49:2564-2571
21. Aschner P, Kipnes M, Lunceford J, Mickel C, Davies M. Herman WD. Sitagliptin monotherapy improved glycemic control in the fasting and postprandial states and beta-cell function after 24 weeks in patients with type 2 diabetes. Diabetes 2006;55:A462.
22. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams Herman DE. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979-1987
23. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Efficacy and safety of dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24 week, multicenter, randomized, double-blind, placebo-controlled, parallel group study. Clin Ther 2006;28:1556-1568
24. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, doubleblind, non-inferiority trial. Diabete Obestet Metab 2007;9:194-205.
25. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase 4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-2643
26. Scott R, Loeys T, Davies MJ, Engel SS. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obestet Metab 2008;10:959-969
27. Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, Amatruda JM, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008;24:537-550
28. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Efficacy and safety of dipeptidyl peptidase-4 inhibitor, sitagliptin in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007;9:733-745
29. Croxtall JD, Keam SJ. Vildagliptin: A review of its use in the management of type 2 diabetes mellitus. Drugs 2008;68:2387-2408